Rajan P Dang1, Valerie H LE2, Brett A Miles3, Marita S Teng3, Eric M Genden3, Richard L Bakst4, Vishal Gupta4, David Y Zhang5, Elizabeth G Demicco5, Marshall R Posner6, Krzysztof J Misiukiewicz6. 1. Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. Rajan.dang@icahn.mssm.edu. 2. Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. 3. Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. 4. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. 5. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A. 6. Department of Hematology-Oncology-Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Abstract
BACKGROUND: There are few data regarding the role of human papilloma virus (HPV) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: A retrospective chart review was carried out using our electronic medical record (EPIC) for all patients diagnosed with HPV-positive R/M HNSCC between 2010 and 2014 with minimum of 6 months of follow-up in order to assess progression-free survival (PFS) and overall survival (OS). RESULTS: We assessed 11 patients who underwent a variety of treatments. PFS and OS were 7 and 34+ months, respectively. Four patients (36%) were still alive and disease-free (median OS of 39+ months). Three disease-free patients had been treated with taxane, platinum and 5-fluorouracil as aggressive curative systemic therapy. Another patient treated with TPF was disease-free for 25 months and died of disease at 42 months. CONCLUSION: Our study demonstrates favorable prognosis for patients with HPV-positive R/M HNSCC and that aggressive systemic treatment can lead to a prolonged disease-free period or possibly cure, even after metastasis. Copyright
BACKGROUND: There are few data regarding the role of human papilloma virus (HPV) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: A retrospective chart review was carried out using our electronic medical record (EPIC) for all patients diagnosed with HPV-positive R/M HNSCC between 2010 and 2014 with minimum of 6 months of follow-up in order to assess progression-free survival (PFS) and overall survival (OS). RESULTS: We assessed 11 patients who underwent a variety of treatments. PFS and OS were 7 and 34+ months, respectively. Four patients (36%) were still alive and disease-free (median OS of 39+ months). Three disease-free patients had been treated with taxane, platinum and 5-fluorouracil as aggressive curative systemic therapy. Another patient treated with TPF was disease-free for 25 months and died of disease at 42 months. CONCLUSION: Our study demonstrates favorable prognosis for patients with HPV-positive R/M HNSCC and that aggressive systemic treatment can lead to a prolonged disease-free period or possibly cure, even after metastasis. Copyright
Authors: Daniel Strüder; Theresa Momper; Nina Irmscher; Mareike Krause; Jan Liese; Sebastian Schraven; Annette Zimpfer; Sarah Zonnur; Ann-Sophie Burmeister; Björn Schneider; Bernhard Frerich; Robert Mlynski; Christina Große-Thie; Christian Junghanss; Claudia Maletzki Journal: J Exp Clin Cancer Res Date: 2021-08-06